IDEXX Laboratories, Inc. (NASDAQ: IDXX) is a large market cap stock with a market cap of 10015.24. It is in the Diagnostic Substances industry and sector Healthcare, with a current P/E of 50.74, a forward P/E of 41.76 and EPS of 2.21. At a stock price of 112.09 (1.76%) it has a dividend yield of *TBA.
EPS growth for the last five years have been 11.60%, more recently this last year it has grown by 14.40%. The next year growth is going to be about 13.68% and more long-term 13.67% after five years. EPS growth quarter over quarter is 22.60%. Sales growth for the past five years have been 7.70% and sales growth quarter over quarter is 12.90%.
For performance, IDEXX Laboratories, Inc. the past week has seen a gain of 1.48%. For the last month performance for IDEXX Laboratories, Inc. is 19.51%. While the last quarter is 28.00% and half year, 48.50%. Finally for the year, performance is 53.11%.
The 52-week high for IDEXX Laboratories, Inc., is at -0.15%, and for the 52-week low it comes to a value of 76.58%. The 20-day simple moving average is 13.14% and 36.65% for the 200-day simple moving average.
Volatility for the week is at 1.46%, and for the month it is 1.72%. IDEXX Laboratories, Inc., has a target price of 115.5.
In terms of debt, long term debt/equity is *TBA, and for total debt/equity IDEXX Laboratories, Inc. has *TBA. The gross margin is 55.00%, while operating margin is 18.70%, the profit margin is 11.90%. The current ratio is 1 and the quick ratio is 0.8.
Insider ownership is at 1.30%, with instituitional ownership at 94.30%. IDEXX Laboratories, Inc. has a payout ratio of 0.00%. With the total shares outstanding coming to 89.35. The shares float is 88.25, with the float short at 4.43%, with short ratio coming to 6.06.
In terms of returns, the return on assets see IDEXX Laboratories, Inc., get 13.60%, with its returns on investment at 22.10%. Return on equity is -392.60%. So will the investors see the target price of 115.5, reached soon?
Disclaimer: Remember there is a risk to your investment, this is not a recommendation, nor personal advice, never invest more than you are able too loose.